ACTU vs TPVG vs IMVT vs HRZN vs HTGC

For growth investors, TriplePoint Venture Growth BDC Corp.

(TPVG) is the stronger pick with 36. 6% revenue growth year-over-year, versus 17. 9% for Horizon Technology Finance Corporation (HRZN). Horizon Technology Finance Corporation (HRZN) offers the better valuation at 4. 2x trailing P/E (6. 5x forward), making it the more compelling value choice. Analysts rate Actuate Therapeutics Inc (ACTU) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Horizon Technology Finance Corporation (HRZN) is the cheapest at 4.

2x versus Hercules Capital, Inc. at 8. 4x. On forward P/E, TriplePoint Venture Growth BDC Corp. is actually cheaper at 6. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Horizon Technology Finance Corporation wins at 0. 27x versus TriplePoint Venture Growth BDC Corp. 's 5. 88x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +213. 0%, compared to -76. 5% for Actuate Therapeutics Inc (ACTU). Over 10 years, the gap is even starker: IMVT returned +237. 9% versus ACTU's -76. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hercules Capital, Inc.

(HTGC) is the lower-risk stock at 0. 64β versus Actuate Therapeutics Inc's 2. 21β — meaning ACTU is approximately 245% more volatile than HTGC relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 149% for Horizon Technology Finance Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TriplePoint Venture Growth BDC Corp.

(TPVG) is pulling ahead at 36. 6% versus 17. 9% for Horizon Technology Finance Corporation (HRZN). On earnings-per-share growth, the picture is similar: Horizon Technology Finance Corporation grew EPS 756. 3% year-over-year, compared to -1. 5% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hercules Capital, Inc.

(HTGC) is the more profitable company, earning 62. 1% net margin versus -6. 6% for Horizon Technology Finance Corporation — meaning it keeps 62. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -4. 0% for HRZN. At the gross margin level — before operating expenses — HTGC leads at 87. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Horizon Technology Finance Corporation (HRZN) is the more undervalued stock at a PEG of 0. 27x versus TriplePoint Venture Growth BDC Corp. 's 5. 88x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, TriplePoint Venture Growth BDC Corp. (TPVG) trades at 6. 0x forward P/E versus 8. 1x for Hercules Capital, Inc. — 2. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ACTU: 939. 6% to $21. 00.

In this comparison, HRZN (28.

8% yield), TPVG (18. 4% yield), HTGC (9. 1% yield) pay a dividend. ACTU, IMVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Hercules Capital, Inc.

(HTGC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 64), 9. 1% yield, +164. 1% 10Y return). Actuate Therapeutics Inc (ACTU) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HTGC: +164. 1%, ACTU: -76. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ACTU (Healthcare) and TPVG (Financial Services) and IMVT (Healthcare) and HRZN (Financial Services) and HTGC (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ACTU is a small-cap quality compounder stock; TPVG is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; HRZN is a small-cap high-growth stock; HTGC is a small-cap high-growth stock. TPVG, HRZN, HTGC pay a dividend while ACTU, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.